Affinity Wealth Management LLC Purchases New Position in Jazz Pharmaceuticals PLC $JAZZ

Key Points

• Affinity Wealth Management LLC has acquired a new stake in Jazz Pharmaceuticals by purchasing 2,627 shares for approximately $279,000.
• Several prominent investors, including Dimensional Fund Advisors LP and JPMorgan Chase & Co., have significantly increased their holdings in Jazz Pharmaceuticals, showing strong institutional interest in the company.
• Wall Street analysts have a consensus rating of "Moderate Buy" for Jazz Pharmaceuticals, with target prices ranging from $151.00 to $205.00 per share, indicating optimism about its future performance.

Affinity Wealth Management LLC purchased a new stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 2,627 shares of the specialty pharmaceutical company's stock, valued at approximately $279,000.

Other large investors have also made changes to their positions in the company. Dimensional Fund Advisors LP lifted its holdings in Jazz Pharmaceuticals by 14.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,328,430 shares of the specialty pharmaceutical company's stock worth $289,066,000 after purchasing an additional 293,360 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in Jazz Pharmaceuticals by 4.7% in the 1st quarter. JPMorgan Chase & Co. now owns 1,662,042 shares of the specialty pharmaceutical company's stock worth $206,343,000 after purchasing an additional 74,501 shares during the last quarter. Fuller & Thaler Asset Management Inc. lifted its holdings in Jazz Pharmaceuticals by 41.7% in the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 1,331,011 shares of the specialty pharmaceutical company's stock worth $165,245,000 after purchasing an additional 391,660 shares during the last quarter. Swedbank AB lifted its holdings in Jazz Pharmaceuticals by 10.0% in the 1st quarter. Swedbank AB now owns 1,102,143 shares of the specialty pharmaceutical company's stock worth $136,831,000 after purchasing an additional 100,211 shares during the last quarter. Finally, Perpetual Ltd lifted its holdings in Jazz Pharmaceuticals by 60.2% in the 1st quarter. Perpetual Ltd now owns 952,172 shares of the specialty pharmaceutical company's stock worth $118,212,000 after purchasing an additional 357,784 shares during the last quarter. Institutional investors own 89.14% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on JAZZ shares. Royal Bank Of Canada boosted their target price on Jazz Pharmaceuticals from $145.00 to $151.00 and gave the stock an "outperform" rating in a report on Thursday, August 28th. Truist Financial boosted their target price on Jazz Pharmaceuticals from $200.00 to $205.00 and gave the stock a "buy" rating in a report on Thursday, August 28th. Morgan Stanley upped their price target on Jazz Pharmaceuticals from $163.00 to $167.00 and gave the stock an "overweight" rating in a report on Wednesday. Deutsche Bank Aktiengesellschaft began coverage on Jazz Pharmaceuticals in a report on Tuesday, July 15th. They set a "buy" rating and a $152.00 price target for the company. Finally, Zacks Research upgraded Jazz Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Friday, August 15th. Fourteen equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $178.93.

Jazz Pharmaceuticals Stock Performance

JAZZ opened at $129.59 on Thursday. The stock has a market cap of $7.86 billion, a PE ratio of -19.26, a P/E/G ratio of 8.02 and a beta of 0.24. The company has a current ratio of 1.62, a quick ratio of 1.37 and a debt-to-equity ratio of 1.17. Jazz Pharmaceuticals PLC has a 1 year low of $95.49 and a 1 year high of $148.06. The stock's 50 day simple moving average is $121.38 and its 200-day simple moving average is $116.07.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($5.61) by ($2.64). The firm had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.05 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The business's revenue for the quarter was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $5.30 earnings per share. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. Sell-side analysts forecast that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Insider Activity

In other news, Director Bruce C. Cozadd sold 6,000 shares of the business's stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $128.62, for a total transaction of $771,720.00. Following the sale, the director directly owned 429,973 shares in the company, valued at approximately $55,303,127.26. The trade was a 1.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 4.30% of the company's stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.